Literature DB >> 11443708

Differential routing of choline in implanted breast cancer and normal organs.

R Katz-Brull1, R Margalit, H Degani.   

Abstract

Choline is an essential nutrient participating as the initial substrate in major metabolic pathways. The differential metabolic routing of choline was investigated in MCF7 human breast cancer implanted in nude mice and in the kidney, liver, and brain of these mice. The distribution of metabolites following infusion of [1,2-(13)C]-choline was monitored by (13)C magnetic resonance spectroscopy. This infusion led to an 18-fold increase in plasma choline and to concomitant changes in the content and distribution of choline metabolites. In vivo kinetic studies of the tumor during the infusion demonstrated accumulation of choline in the interstitium and intracellular synthesis of phosphocholine. The amount of unlabeled choline metabolites was 7.1, 4.1, 3.5, and 1.4 micromol/g in the kidney, liver, tumor, and brain, respectively. The variations in the labeled metabolites were more pronounced with high amounts in the kidney and liver (8.0 and 4.3 micromol/g, respectively) and very low amounts in the tumor and brain (0.33 and 0.12 micromol/g, respectively). In the kidney and liver, betaine (unlabeled and labeled) was the predominant choline metabolite. The dominant unlabeled metabolite in breast cancer was phosphocholine and in the brain glycerophosphocholine. Magn Reson Med 46:31-38, 2001. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11443708     DOI: 10.1002/mrm.1157

Source DB:  PubMed          Journal:  Magn Reson Med        ISSN: 0740-3194            Impact factor:   4.668


  13 in total

Review 1.  Metabolic effects of signal transduction inhibition in cancer assessed by magnetic resonance spectroscopy.

Authors:  Siver Andreas Moestue; Olav Engebraaten; Ingrid Susann Gribbestad
Journal:  Mol Oncol       Date:  2011-04-23       Impact factor: 6.603

Review 2.  In vivo magnetic resonance spectroscopy of liver tumors and metastases.

Authors:  E G W ter Voert; L Heijmen; H W M van Laarhoven; A Heerschap
Journal:  World J Gastroenterol       Date:  2011-12-21       Impact factor: 5.742

3.  Quantification of choline-containing compounds in malignant breast tumors by 1H MR spectroscopy using water as an internal reference at 1.5 T.

Authors:  Hyun-Man Baik; Min-Ying Su; Hon Yu; Rita Mehta; Orhan Nalcioglu
Journal:  MAGMA       Date:  2006-05-09       Impact factor: 2.310

Review 4.  MRS and MRSI guidance in molecular medicine: targeting and monitoring of choline and glucose metabolism in cancer.

Authors:  Kristine Glunde; Lu Jiang; Siver A Moestue; Ingrid S Gribbestad
Journal:  NMR Biomed       Date:  2011-07       Impact factor: 4.044

5.  Choline PET for monitoring early tumor response to photodynamic therapy.

Authors:  Baowei Fei; Hesheng Wang; Chunying Wu; Song-mao Chiu
Journal:  J Nucl Med       Date:  2009-12-15       Impact factor: 10.057

6.  Molecular Imaging of Cancer: Applications of Magnetic Resonance Methods.

Authors:  Barjor Gimi; Arvind P Pathak; Ellen Ackerstaff; Kristine Glunde; Dmitri Artemov; Zaver M Bhujwalla
Journal:  Proc IEEE Inst Electr Electron Eng       Date:  2005-04-01       Impact factor: 10.961

7.  Capillary electrophoresis mass spectrometry-based saliva metabolomics identified oral, breast and pancreatic cancer-specific profiles.

Authors:  Masahiro Sugimoto; David T Wong; Akiyoshi Hirayama; Tomoyoshi Soga; Masaru Tomita
Journal:  Metabolomics       Date:  2009-09-10       Impact factor: 4.290

8.  Detection of choline signal in human breast lesions with chemical-shift imaging.

Authors:  Hyeon-Man Baek; Jeon-Hor Chen; Hon J Yu; Rita Mehta; Orhan Nalcioglu; Min-Ying Su
Journal:  J Magn Reson Imaging       Date:  2008-05       Impact factor: 4.813

9.  Characterization of breast cancers and therapy response by MRS and quantitative gene expression profiling in the choline pathway.

Authors:  David L Morse; Danielle Carroll; Sam Day; Heather Gray; Pooja Sadarangani; Shiva Murthi; Constantin Job; Brenda Baggett; Natarajan Raghunand; Robert J Gillies
Journal:  NMR Biomed       Date:  2009-01       Impact factor: 4.044

10.  Aberrant activation of super enhancer and choline metabolism drive antiandrogen therapy resistance in prostate cancer.

Authors:  Simeng Wen; Yundong He; Liewei Wang; Jun Zhang; Changyi Quan; Yuanjie Niu; Haojie Huang
Journal:  Oncogene       Date:  2020-09-11       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.